Long-term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex
- 1 September 1990
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 336 (8714), 526-529
- https://doi.org/10.1016/0140-6736(90)92085-v
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- Once-Daily Administration of 2′,3′-Dideoxyinosine (ddI) in Patients with the Acquired Immunodeficiency Syndrome or AIDS-Related ComplexNew England Journal of Medicine, 1990
- 2′,3′-Dideoxyinosine (ddI) in Patients with the Acquired Immunodeficiency Syndrome or AIDS-Related ComplexNew England Journal of Medicine, 1990
- Bone Marrow Toxicity of DideoxyinosineNew England Journal of Medicine, 1989
- In Vivo Activity Against HIV and Favorable Toxicity Profile of 2′,3′-DideoxyinosineScience, 1989
- Replication of human immunodeficiency virus in monocytes. Granulocyte/macrophage colony-stimulating factor (GM-CSF) potentiates viral production yet enhances the antiviral effect mediated by 3'-azido-2'3'-dideoxythymidine (AZT) and other dideoxynucleoside congeners of thymidine.The Journal of Experimental Medicine, 1989
- Hypertriglyceridemia in the acquired immunodeficiency syndromeAmerican Journal Of Medicine, 1989
- Initial studies on the cellular pharmacology of 2′,3′-dideoxyinosine, an inhibitor of HIV infectivityBiochemical Pharmacology, 1987
- Long-term inhibition of human T-lymphotropic virus type III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2',3'-dideoxynucleosides in vitro.Proceedings of the National Academy of Sciences, 1987
- Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides.Proceedings of the National Academy of Sciences, 1986
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958